Related references
Note: Only part of the references are listed.Bone cell-independent benefits of raloxifene on the skeleton: A novel mechanism for improving bone material properties
Maxime A. Gallant et al.
BONE (2014)
A Review of Rodent Models of Type 2 Diabetic Skeletal Fragility
Roberto J. Fajardo et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes
Hiroko Mori et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2013)
Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Selective estrogen receptor modulation in pancreatic β-cells and the prevention of type 2 diabetes
Joseph P. Tiano et al.
ISLETS (2012)
Risk of Newly Diagnosed Type 2 Diabetes Is Reduced in Users of Alendronate
Peter Vestergaard
CALCIFIED TISSUE INTERNATIONAL (2011)
Effects of the Combination Treatment of Raloxifene and Alendronate on the Biomechanical Properties of Vertebral Bone
Tamim Diab et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes
Joseph P. Tiano et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment
Mihoko Matsumura et al.
MEDICAL PRINCIPLES AND PRACTICE (2010)
Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models
Susan Reinwald et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic Complications
Masahiro Yamamoto et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effects of 1 to 3 Years' Treatment with Alendronate on Mechanical Properties of the Femoral Shaft in a Canine Model: Implications for Subtrochanteric Femoral Fracture Risk
David B. Burr et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2009)
Raloxifene enhances material- level mechanical properties of femoral cortical and trabecular bone
Matthew R. Allen et al.
ENDOCRINOLOGY (2007)
Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture
Mohsen Janghorbani et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Raloxifene enhances vertebral mechanical properties independent of bone density
Matthew R. Allen et al.
BONE (2006)
Prospective study of diabetes and risk of hip fracture - The Nurses' Health Study
Mohsen Janghorbani et al.
DIABETES CARE (2006)
Skeletal effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) study
ES Siris et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults - The health, aging, and body composition study
ES Strotmeyer et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density:: results of EFFECT (EFficacy of FOSAMAX® versus EVISTA® Comparison Trial) International
PN Sambrook et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Lifetime risk for diabetes mellitus in the United States
KMV Narayan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Post hoc analysis of data from the multiple outcomes of raloxifene evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes
E Barrett-Connor et al.
CLINICAL THERAPEUTICS (2003)
Share Paper
